Second-Line and Subsequent Therapies after Atezolizumab Plus Bevacizumab Treatment in Hepatocellular Carcinoma: A Multicenter Prospective Cohort Study.

Gut Liver · 2026 · PMC13364757 · PMID 41944032

Europe PMC DOI

hedged sentences

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

showed a trendp=0.051so close (0.05 < p ≤ 0.1)

Among 48 patients receiving 3L therapy, regorafenib showed a trend toward improved OS over sorafenib (HR, 0.33; 95% CI, 0.11 to 1.02; p=0.051), supported by restricted mean survival time analysis (p=0.028).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The AE profile differences across the 3L therapies did not reach statistical significance ( Supplementary Table 6 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.